Delcath Systems, Inc.

NASDAQ:DCTH

Medical - Devices

Healthcare
$19.70 -1.91%

-$0.23 today

Market cap
$685.32M
Beta
0.52
P/E (TTM)
751.4
EPS (TTM)
$0.02
52W Low $8.12High $14.48

Volume 0.59M

Average 0.42M

DCTH Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Delcath Systems, Inc.NASDAQ: DCTH

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $9.82M rose 96.2% year over year, behind the +124.4% change in trailing-twelve-month research & development. Sequentially, it rose 4.8% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.

Context

  • Research & development amounted to 34.3% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +96.2% toward the trailing-twelve-month pace of +124.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.82M+4.8% QoQ
Last fiscal yearDec 2025
$29.25M+110.8% YoY
LTMMar 2026
$34.06M+124.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.2%——
1 year+110.8%——
3-year CAGR+16.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
29.25M USD
Year-over-year change
+110.8%
4-year CAGR
+20.7%

Research & Development vs competitors

How DCTH compares with its peers on the latest reported figures

  • DCTH's LTM Mar 2026 research & development of $34.06M is the 3rd highest of the 4 companies compared; the peer median is $85.68M.
  • Its year-over-year change of +124.4% is the highest of 4, against a peer median of +8.2%.
  • Research & development amounts to 37.7% of revenue for DCTH, versus a peer median of 34.0%.
DCTH Competitors Peer median
Research & Development for DCTH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$229.1M +8.2%+2.9%34.0%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M +76.6%+218.7%13864.6%
DCTHDelcath Systems, Inc.LTM Mar 2026$34.06M +124.4%+16.3%37.7%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$14.89M -1.7%-11.2%33.2%
Peer median (excluding DCTH) $85.68M+8.2%+2.9%34.0%

Competitors are the stored peer set for DCTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.56M2.72M2.07M37.21M85.23M
Cost of Revenue671K686K635K6.19M11.8M
Gross Profit2.88M2.03M1.43M31.02M73.43M
Gross Margin81.1%74.8%69.2%83.4%86.2%
Research & Development13.78M18.58M17.5M13.87M29.25M
Selling, General & Admin13.64M17.3M22.11M29.55M43.53M
Operating Expenses27.42M35.89M39.61M43.43M72.77M
Depreciation & Amortization146K132K399K229K349K
EBITDA(24.32M)(33.69M)(45.84M)(26.16M)3.86M
EBITDA Margin-684.0%-1239.1%-2219.9%-70.3%4.5%
Operating Income(24.53M)(33.85M)(38.18M)(12.41M)660K
Operating Margin-690.0%-1245.1%-1849.0%-33.4%0.8%
Interest Income000125K2.92M
Interest Expense1.19M2.69M1.44M00
Other Income / Expenses(1.12M)(2.66M)(9.5M)(13.98M)2.85M
Income Before Tax(25.65M)(36.51M)(47.68M)(26.39M)3.51M
Pre-Tax Margin-721.5%-1342.7%-2308.9%-70.9%4.1%
Income Tax Expense0000810K
Net Income(25.65M)(36.51M)(47.68M)(26.39M)2.7M
Net Margin-721.5%-1342.7%-2308.9%-70.9%3.2%
EPS (Basic)(3.59)(4.12)(2.94)(0.93)0.08
EPS (Diluted)(3.59)(4.12)(2.94)(0.93)0.07
Weighted Avg Shares7.15M8.86M16.23M28.51M35.82M
Weighted Avg Shares (Diluted)7.15M8.86M16.23M28.51M39.92M

Delcath Systems, Inc.

NASDAQ:DCTH

Intrinsic Alpha fair value

Locked

Current Price

$19.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.